MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-13-2026
Exact Sciences Corporation Operating Income 2011-2026 | EXAS
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Exact Sciences Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -206 M | -1.05 B | -215 M | -594 M | -856 M | -768 M | -234 M | -159 M | -118 M | -169 M | -159 M | -101 M | -46.8 M | -52.6 M | -28.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -28.8 M | -1.05 B | -317 M |
Quarterly Operating Income Exact Sciences Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -25.5 M | -2.15 M | -96 M | - | -39.4 M | -26.3 M | -107 M | - | 6.85 M | -76.9 M | -77.1 M | - | -138 M | -160 M | -177 M | - | -162 M | -172 M | -301 M | - | -203 M | -67 M | -82.4 M | -96.1 M | -35.7 M | -33.9 M | -68.1 M | -49.3 M | -40.9 M | -32.7 M | -36.5 M | -23 M | -28.4 M | -31.4 M | -35.5 M | -37.7 M | -38.3 M | -45.1 M | -47.9 M | -40.4 M | -43.3 M | -39.4 M | -36 M | -32.6 M | -32.2 M | -19.6 M | -16.2 M | -12.3 M | -11.2 M | -12.4 M | -10.9 M | -14 M | -13 M | -14.9 M | -10.7 M | -9.94 M | -7.84 M | -6.64 M | -4.4 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.85 M | -301 M | -55.1 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B |  USA |
 |
Fulgent Genetics
FLGT
|
-91.1 M | $ 17.11 | -1.55 % | $ 527 M | USA |
 |
Agilent Technologies
A
|
1.35 B | $ 114.96 | 0.15 % | $ 34.9 B | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 116.78 | 0.18 % | $ 9.63 B |  Irlanda |
 |
Celcuity
CELC
|
-172 M | $ 138.23 | -3.02 % | $ 6.46 B | USA |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Illumina
ILMN
|
-833 M | $ 144.41 | -0.29 % | $ 23 B | USA |
 |
Co-Diagnostics
CODX
|
-50.2 M | $ 5.07 | 36.66 % | $ 6.74 M | USA |
 |
Castle Biosciences
CSTL
|
-42.8 M | $ 20.15 | -1.9 % | $ 584 M | USA |
 |
Aspira Women's Health
AWH
|
-7.91 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-35.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Guardant Health
GH
|
-437 M | $ 118.95 | 0.8 % | $ 14.9 B | USA |
 |
CareDx, Inc
CDNA
|
-30.8 M | $ 21.63 | 0.28 % | $ 1.15 B | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-2.37 M | - | - | $ 9.42 M |  Israel |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Interpace Biosciences
IDXG
|
4.08 M | $ 1.82 | 1.11 % | $ 8.05 M | USA |
 |
Lantheus Holdings
LNTH
|
311 M | $ 103.0 | 9.03 % | $ 6.95 B | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M |  China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
NeoGenomics
NEO
|
-116 M | $ 9.23 | 1.32 % | $ 1.18 B | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
National Research Corporation
NRC
|
22.6 M | $ 19.08 | 0.21 % | $ 427 M | USA |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 160.3 | 0.91 % | $ 7.95 B | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Medpace Holdings
MEDP
|
535 M | $ 432.8 | 0.63 % | $ 12.5 B | USA |
 |
Natera
NTRA
|
-541 M | $ 203.19 | -0.25 % | $ 20 B | USA |
 |
Myriad Genetics
MYGN
|
-387 M | $ 3.82 | -2.3 % | $ 354 M | USA |
 |
Personalis
PSNL
|
-88.1 M | $ 8.47 | 2.67 % | $ 756 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
1.42 B | $ 26.95 | -0.74 % | $ 25.6 B |  Niderland |
 |
Senseonics Holdings
SENS
|
-68.3 M | $ 6.34 | 2.92 % | $ 265 M | USA |
 |
QIAGEN N.V.
QGEN
|
466 M | - | - | $ 10.6 B | Niderland |
 |
Soleno Therapeutics
SLNO
|
9.41 M | - | - | $ 2.69 B | USA |
 |
Twist Bioscience Corporation
TWST
|
-136 M | $ 60.57 | 2.95 % | $ 3.62 B | USA |
 |
Biomerica
BMRA
|
-5.14 M | $ 2.49 | 2.05 % | $ 5.72 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 259.93 | 1.63 % | $ 21.6 B | USA |
 |
Thermo Fisher Scientific
TMO
|
7.75 B | $ 448.28 | -0.24 % | $ 169 B | USA |
 |
Trinity Biotech plc
TRIB
|
-21.2 M | $ 0.6 | -3.7 % | $ 216 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Waters Corporation
WAT
|
271 M | $ 342.37 | 0.4 % | $ 20.4 B | USA |
 |
Neogen Corporation
NEOG
|
-1.06 B | $ 8.9 | 0.45 % | $ 1.93 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.56 B | $ 195.21 | 0.72 % | $ 21.7 B | USA |